Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease

• Carl I. Webster ,

  * E-mail: websterc@medimmune.com

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Matthew Burrell,

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Lise-Lotte Olsson,

  Affiliation Discovery Sciences, AstraZeneca R & D, Mölndal, Sweden

  ⨯
• Susan B. Fowler,

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Sarah Digby,

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Alan Sandercock,

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Arjan Snijder,

  Affiliation Discovery Sciences, AstraZeneca R & D, Mölndal, Sweden

  ⨯
• Jan Tebbe,

  Affiliation Global Drug Discovery, Global Biologics, Bayer HealthCare AG, Cologne, Germany

  ⨯
• Ulrich Haupts,

  Affiliation Global Drug Discovery, Global Biologics, Bayer HealthCare AG, Cologne, Germany

  ⨯
• Joanna Grudzinska,

  Affiliation Global Drug Discovery, Global Biologics, Bayer HealthCare AG, Cologne, Germany

  ⨯
• Lutz Jermutus,

  Affiliation Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom

  ⨯
• Christin Andersson

  Affiliation CNS&P iMed, AstraZeneca R & D, Södertälje, Sweden

  ⨯